Administration is mostly associated with fever (44.2%). Occasionally patients experience a flu like syndrome consisting of fever, chills, bone pain and/or arthralgia (10%) and myalgia.
Gastrointestinal reactions such as nausea/vomiting (29%/14%) and anorexia (9%) have been reported following administration. Injection site reactions such as erythema, redness or swelling were observed infrequently and resolved in most cases without treatment within 24-48 hrs.
Azotemia (2%) has been reported during therapy with zoledronic acid, serum creatinine should be monitored.
Electrolyte imbalances may occur during treatment with zoledronic acid. Hypocalcaemia (1.2%), hypomagnesemia (10%) and hypophosphatemia (52%) have been reported. Monitor serum calcium, phosphate and magnesium during therapy, short term supplementation of these electrolytes may be necessary.
View ADR Monitoring Form